Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | MLYCD | O95822 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | LATS1 | O95835 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | UBE2N | P61088 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.30 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3403873 | 0.91 | MEN1 (0.34) | KMT2AMEN1ALDH1A1KDM4ENPC1 | |
| SCHEMBL3404511 | 0.88 | S1PR1 (0.39) | MLYCDKMT2AMEN1S1PR1 | |
| SCHEMBL3401788 | 0.86 | MEN1 (0.36) | MLYCDKMT2AMEN1NPC1UBE2N | |
| SCHEMBL3404000 | 0.85 | CA2 (0.39) | KMT2AMEN1NPC1UBE2NS1PR1 | |
| SCHEMBL3403090 | 0.85 | TMPRSS15 (0.33) | CYP1A2CYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL3406516 | 0.85 | BCHE (0.38) | CYP1A2CYP2C9CYP2C19ALDH1A1LATS1 | |
| SCHEMBL3403831 | 0.84 | NPC1 (0.34) | KMT2AMEN1NPC1UBE2N | |
| SCHEMBL3403750 | 0.84 | MAPT (0.32) | ALDH1A1NPC1 | |
| SCHEMBL3408849 | 0.82 | MLYCD (0.40) | MLYCDKMT2APDE10AALDH1A1KDM4E | |
| SCHEMBL3402021 | 0.81 | MEN1 (0.31) | KMT2AMEN1NPC1UBE2NS1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1368342-B3 | BENZIMIDAZOLE AND PYRIDYLIMIDAZOLE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | NEUROGEN CORP (US) | 2010-12-01 | — | — | EP | claimed |
| EP-1370260-B1 | AZOLES AS MALONYL-COA DECARBOXYLASE INHIBITORS USEFUL AS METABOLIC MODULATORS | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2010-11-24 | — | — | EP | claimed |
| EP-1368342-B1 | BENZIMIDAZOLE AND PYRIDYLIMIDAZOLE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | NEUROGEN CORP (US) | 2005-09-07 | — | — | EP | claimed |
| US-20040092503-A1 | Azoles as malonyl-coa decarboxylase inhibitors useful as metabolic modulators | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2004-05-13 | — | — | US | claimed |
| EP-1370260-A2 | AZOLES AS MALONYL-COA DECARBOXYLASE INHIBITORS USEFUL AS METABOLIC MODULATORS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-12-17 | — | — | EP | claimed |
| WO-2002066035-A2 | AZOLES AS MALONYL-COA DECARBOXYLASE INHIBITORS USEFUL AS METABOLIC MODULATORS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2002-08-29 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092503-A1 | Azoles as malonyl-coa decarboxylase inhibitors useful as metabolic modulators | ME1, ME3, ME2 | CYP1A2 236/4885CYP2C9 214/4885CYP2C19 379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.